NCT05561075

Oral Bioavailability of Pterostilbene Cocrystal Compared to Its Free Form (BIOPTERO)

Evaluation of the Oral Bioavailability of Pterostilbene Cocrystal Compared to Its Free Form in Healthy Volunteers. Crossover, Randomized, Double-Blind Study (BIOPTERO)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Fundació Eurecat · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

Oxidative stress and reactive oxygen species (ROS) can seriously affect cells, tissues and organs. The human body is capable of counteracting ROS production by stimulating antioxidant defense systems and consequently adapting to the oxidative challenge. Several transcription factors are involved in the induction of antioxidant genes. Activators of nuclear factor derived from erythroid 2 (NRF2), a protein that controls the expression of certain genes, are considered agents capable of inducing antioxidant capacity and to alleviate ROS. There are some food bioactive compounds, including polyphenols, capable of activating NRF2. Pterostilbene (PT) is a stilbenoid found in many natural sources, and is emerging as an antioxidant due to its potential preventive and therapeutic properties in a long list of diseases. Despite its apparent properties, the water solubility and bioavailability of PT are low. The co-crystallization of nutraceuticals is a recent strategy based on crystal engineering to overcome their low solubility and, therefore, their low oral bioavailability. It has been identified and characterized a cocrystal of pterostilbene that can increase oral bioavailability in animals by up to 10 times compared to the commercial free base PT. The main objective of the study is to evaluate the oral bioavailability of the crystallized form of pterostilbene (ccPT) compared to its commercial free base form (pterostilbene (PT). The secondary objectives of the study are to determine the pharmacokinetic parameters: * Relative oral bioavailability (Frel) * Maximum concentration (Cmax). * Maximum time (Tmax). * Half life time (T1/2). During the study there will be 3 visits: a preselection visit (V0), a visit for the first postprandial study (V1) and after one week washing period, a visit for the second postprandial study (V2).

Conditions

• Biological Availability

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Pterostilbene cocrystal	One capsule with Pterostilbene cocrystal
DIETARY_SUPPLEMENT	Pterostilbene free form	One capsule with Pterostilbene free form

Timeline

• Start date: 2022-10-20
• Primary completion: 2022-11-17
• Completion: 2022-11-17
• First posted: 2022-09-30
• Last updated: 2023-03-16

Locations

1 site across 1 country: Spain